FLT3 and hematologic disorder: Genomic characterization of pediatric hematologic malignancies in our cohort identified potential therapeutic targets in nearly 40% of patients (7/18, 38.9%), including the consideration of inhibitors targeting MEK (n=3), receptor tyrosine kinases (ALK n=2, PDGFRB n=1), FLT3 (n=1), and PD-L1 (n=1) (28, 40, 41, 58–60, 85, 97) (Table 1).